^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Waldenstrom Macroglobulinemia

    Related cancers:
    2d
    Crescentic IgM-κ Monoclonal Immunoglobulin Deposition Disease with Thrombotic Microangiopathy in Waldenström's Macroglobulinemia: A Rare and Aggressive Monoclonal Gammopathy of Renal Significance Presentation - A Case Report and Literature Review. (PubMed, Glomerular Dis)
    It highlights the diagnostic challenge of seronegative RPGN, in which MIDD should be included in the differential diagnosis. The case underscores the importance of integrated histopathology and hematologic genomics in identifying rare MGRS entities, recognizing that severe kidney injury may evolve rapidly despite appropriate management.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    2d
    Composite CLL/SLL and Lymphoplasmacytic Lymphoma with IgM Anti-MAG Neuropathy: Clinicopathologic and Molecular Characterization of a Diagnostically Challenging Case. (PubMed, Ann Clin Lab Sci)
    This case highlights the diagnostic complexity of composite indolent B-cell lymphomas and underscores the importance of integrated clinical, morphologic, immunophenotypic, and molecular assessment to inform management and surveillance.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    cytarabine • Brukinsa (zanubrutinib)
    2d
    MYD88L265P mutation is a highly specific marker for the nonGCB/ABC DLBCL molecular subtype. (PubMed, Virchows Arch)
    In DLBCL MYD88 L265P mutation is found in 32% of cases and it is significantly more prevalent in cases with the non-GCB phenotype (OR 5.78 p value = 2.07 × 10⁻⁵) and in DLBCL of extranodal locations (OR = 5.44 p value p < 0.001), including, not only immuneprivileged sites but also the skin, breast, upper respiratory tract, adrenal gland and bone and soft tissues. MYD88L265P mutation is highly specific of the non-GCB type DLBCL, likely reflecting MCD/C5 genetic features in a subset of non-GCB/ABC DLBCL.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    5d
    A Long-term Extension Study of PCI-32765 (Ibrutinib) (clinicaltrials.gov)
    P3, N=700, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2027 --> Dec 2029
    Trial completion date
    |
    Imbruvica (ibrutinib)
    7d
    Preliminary Assessment of [18F]BL40 in PET/CT Scans (clinicaltrials.gov)
    P=N/A, N=10, Completed, British Columbia Cancer Agency | Not yet recruiting --> Completed | N=30 --> 10
    Trial completion • Enrollment change
    13d
    Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    14d
    A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=92, Not yet recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P1/2 trial
    |
    lacutoclax (LP-108) • rocbrutinib (LP-168)
    15d
    Rifaximin in Patients With Monoclonal Gammopathy (clinicaltrials.gov)
    P1, N=50, Completed, Emory University | Active, not recruiting --> Completed
    Trial completion
    21d
    Loncastuximab Tesirine in WM (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Shayna Sarosiek, MD | Recruiting --> Active, not recruiting | N=36 --> 21
    Enrollment closed • Enrollment change
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Zynlonta (loncastuximab tesirine-lpyl)
    21d
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
    P=N/A, N=200, Terminated, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2028 --> May 2026 | Recruiting --> Terminated | Trial primary completion date: Feb 2027 --> May 2026; No longer a research question to answer.
    Trial completion date • Trial termination • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
    23d
    HEMO-CONNECT: Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Centre Hospitalier de la côte Basque
    New trial
    28d
    BAF-FRontier-1: A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) (clinicaltrials.gov)
    P1, N=215, Not yet recruiting, Eli Lilly and Company | Trial completion date: Mar 2029 --> Sep 2029
    Trial completion date • First-in-human